Toronto Dominion Bank Raises Stake in Illumina, Inc. (NASDAQ:ILMN)

Toronto Dominion Bank boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 38.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,838 shares of the life sciences company’s stock after purchasing an additional 8,578 shares during the quarter. Toronto Dominion Bank’s holdings in Illumina were worth $4,022,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Empowered Funds LLC raised its position in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after purchasing an additional 66 shares during the last quarter. Caprock Group LLC increased its holdings in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares in the last quarter. Integrated Advisors Network LLC boosted its position in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after buying an additional 90 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its position in shares of Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 1.7 %

Shares of ILMN stock opened at $143.87 on Monday. The company’s fifty day simple moving average is $144.27 and its two-hundred day simple moving average is $128.63. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a market cap of $22.82 billion, a P/E ratio of -14.44 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Piper Sandler reduced their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. StockNews.com began coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating on the stock. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and an average target price of $165.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.